GLP-1 Drug Exenatide Builds Stronger Bones Than Insulin in Diabetic Rats with Implants | Research

The takeaway

The GLP-1 peptide drug exenatide promotes significantly better bone formation and implant integration than insulin in diabetic rats through Wnt pathway activation and anti-inflammatory mechanisms.

Exenatide extensively promoted osseointegration
Compared to insulin, the GLP-1 peptide drug activated bone-building (Wnt), suppressed fat formation (BMPR1A), and reduced inflammation (β-TrCP) — a triple mechanism for superior bone healing in diabetes.

What the researchers found

The GLP-1 receptor agonist exenatide significantly outperformed insulin in promoting bone formation and implant integration in diabetic rats. Exenatide extensively promoted peri-implant osseointegration through the LRP5/6/GSK-3β/β-catenin Wnt signaling pathway, while also inhibiting fat formation (via BMPR1A suppression) and reducing inflammation (via β-TrCP). Both in vivo micro-CT analysis and in vitro bone marrow stromal cell experiments confirmed exenatide's superior osteogenic effects compared to insulin.

Why it matters

Type 2 diabetes significantly increases the risk of poor bone healing and implant failure. This study reveals that the choice of diabetes medication matters for bone health — exenatide (a GLP-1 peptide drug) not only controls blood sugar but actively promotes bone formation through multiple mechanisms. This adds 'bone protection' to the growing list of GLP-1 RA benefits beyond glycemic control and could influence treatment decisions for diabetic patients needing dental or orthopedic implants.

The numbers in context

Exenatide vs insulin vs PBS · micro-CT bone analysis · dual-fluorescent labeling · LRP5/6/GSK-3β/β-catenin Wnt pathway activated · BMPR1A suppressed (anti-lipogenesis) · β-TrCP upregulated (anti-inflammation) · T2D rat model

How the study worked

In vivo: Diabetic rats received dental implants and were treated with exenatide, insulin, or PBS. Peri-implant bone was assessed by micro-CT, histology, dual-fluorescent labeling, immunofluorescence, and immunohistochemistry. In vitro: Bone marrow mesenchymal stromal cells from T2D rats were treated with exenatide, insulin, or PBS, and osteogenesis-related and Wnt signaling gene/protein expression was measured by RT-PCR and Western blotting.

Who was studied

Type 2 diabetic rats with dental implants and bone marrow stromal cells from T2D rats

What this study cannot tell us

This is a rat model study, and bone biology differs between rodents and humans. The study used a T2D model with implants — results may not generalize to other bone healing scenarios. Long-term bone maintenance effects were not assessed. The exenatide doses used in rats may not translate directly to human clinical doses. The study did not compare newer GLP-1 RAs like semaglutide or tirzepatide.

How to read the evidence

This is a well-designed preclinical study combining in vivo implant studies in diabetic rats with in vitro mechanistic experiments in bone marrow stromal cells. The convergent evidence from multiple techniques is strong, though human validation is needed.

When this study was published

Published in 2024, this study reflects growing interest in the extra-glycemic effects of GLP-1 drugs, including their impact on bone metabolism.

The bigger picture

This study adds bone health to the expanding list of GLP-1 RA benefits beyond blood sugar control. As the population ages and the overlap between diabetes and osteoporosis/implant needs grows, the finding that GLP-1 drugs actively promote bone formation could influence treatment guidelines. It also raises the intriguing possibility that GLP-1 drugs might be useful for non-diabetic patients with poor bone healing.

Questions still open

Do GLP-1 RAs like semaglutide show similar or even greater bone-building effects compared to exenatide?
Could GLP-1 drugs be prescribed specifically to improve implant outcomes in diabetic patients?
Do the bone-building effects of GLP-1 RAs translate to reduced fracture risk in human diabetic populations?

Common questions

Why do diabetic patients have problems with bone healing and implants?

High blood sugar damages blood vessels that supply bone with nutrients, impairs the function of bone-building cells (osteoblasts), promotes inflammation, and increases fat cell formation in bone marrow — all of which weaken bone structure and reduce the ability to heal after surgery or integrate with implants. This is why diabetic patients have higher rates of implant failure and fractures.

How does exenatide help build bone?

Exenatide activates the Wnt/β-catenin signaling pathway, which is the master switch for bone formation. It also suppresses BMPR1A, which reduces fat cell formation in bone marrow (fat cells compete with bone cells for space), and promotes β-TrCP, which reduces inflammation. Together, these three mechanisms create a bone-friendly environment that promotes healing and implant integration.

Read the original research

Role of LRP5/6/GSK-3β/β-catenin in the differences in exenatide- and insulin-promoted T2D osteogenesis and osteomodulation.

British journal of pharmacology, 181(19), 3556-3575

View on PubMed ↗Publisher’s paper ↗

Citation

Chen, Zijun; Wang, Yuxi; Zhang, Guanhua; Zheng, Jian; Tian, Lei; Song, Yingliang; Liu, Xiangdong. (2024). Role of LRP5/6/GSK-3β/β-catenin in the differences in exenatide- and insulin-promoted T2D osteogenesis and osteomodulation.. British journal of pharmacology, 181(19), 3556-3575. https://doi.org/10.1111/bph.16421